Genoa

• Time restricted Eating And Metformin (TEAM) in invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS). A randomized, phase IIb, win … Pending
  2024-518402-40-00 4 Luminal (ER+ve and/or PgR+ve >=1%) invasive breast cancer or ductal ca
• Clinical trial investigating the efficacy of gilteritinib and chemotherapy treatment in patients with Acute myeloid leukemia Pending
  2024-518617-25-00 4 newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
• A low-intervention prospective-retrospective study to evaluate the pharmacokinetics of elexacaftor/tezacaftor/ivacaftor combination in a Cys … Pending
  2024-518785-28-00 6 Cystic Fibrosis
• Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in pa … Pending
  2024-518892-72-00 4 Head and neck cancer
• Use of pegfilgrastim in severe chronic neutropenia Pending
  2024-519009-36-01 4 Severe chronic neutropenia (SCN)
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm … Pending
  2024-519087-41-00 5 Breast cancer is the most common form of cancer among women in North A
• A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a … Pending
  2024-519403-10-00 6 Female contraception.
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Deflazacort TREATment in LMNArelated Pending
  2024-519672-12-00 4 Laminopathies
• EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics (RAPID) Pending
  2024-520067-13-00 6 Bloodstream Infection, Ventilator Associated Pneumonia and Hospital-Ac
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 4 Non-small cell lung cancer (NSCLC)
• 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending
  2025-520861-29-00 5 Prostate cancer at risk of developing metastatic lesions
• Use of the diagnostic PET with 64CuCl2 in order to select patients, in which a disease relapse is shown after prostate surgical removal, to … Pending
  2025-520868-17-00 5 Cancer on the prostatic bed
• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending
  2025-520923-25-00 5 Juvenile Idiopathic Arthritis
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease Pending
  2025-521154-42-00 4 Sickle Cell Disease
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• Clinical study for patients aged between 6 and 11 years, suffering from non-streptococcal pharyngotonsillitis, who will take the marketed dr … Pending
  2025-521526-15-00 6 NON STREPTOCOCCAL PHARYNGOTONSILLITIS
• Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending
  2025-521583-35-00 4 non-small cell lung cancer (NSCLC)
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of ly … Pending
  2025-521827-61-00 4 refractory/relapsed multiple myeloma
• Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL Pending
  2025-522019-40-00 9 relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+)

Showing 25–48 of 660 trials